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CD3 blockage by anti-CD3 monoclonal antibodies pre-
vents the expression of TCR and activation of T lymphocytes,ntroduction
he immune response in inﬂammatory connective tissue dis-
ases depends on the antigen presentation by the T cell
eceptor complex (TCR) and cell Major Histocompatibility
omplex (MHC), of the cytoplasmic signal transduction involv-Please cite this article in press as: Lopes FP, et al. Reduced activation
uation of clinical and 99mTc-OKT3 scintigraphic response in a pati
http://dx.doi.org/10.1016/j.rbre.2015.08.011
ng CD3 complex leading to activation, of the proliferative
esponse of T lymphocytes and of cytokine production.1
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icenses/by-nc-nd/4.0/).The CD3 molecular complex is critical and must necessarily
be present on the surface of T lymphocytes for the occur-
rence TCR expression by the cell,2 while the absence of CD3
chain blocks the development of T lymphocytes, preventing
TCR expression and T-cell activation.3 and CD3 lymphocyte recruitment after TNF-inhibitor use: eval-
ent with juvenile idiopathic arthritis. Rev Bras Reumatol. 2016.
extending transplant survival.4 There is an intrinsic rela-
tionship among antigen presentation, T cell activation,
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transplanted tissue rejection, and production of TNF-alpha,
depending on the presence of a CD3 molecule.5
In Juvenile idiopathic arthritis (JIA), the antigen presenta-
tion by dendritic cells and the lymphocyte activation depend
on the relation TCR/MHC, and consequently on CD3 complex,
acting on TNF-alpha production – a fact of great importance
in the pathophysiology of the disease and in perpetuating
mechanisms of a chronic synovial inﬂammation process.6
Currently, the treatment with anti-TNF inhibitors has been
used to control JIA; the use of this antibody allows the decrease
of the inﬂammatory process and bone injury, with an effec-
tive control of the signs and symptoms of the disease.7 This
medication acts on circulating molecules and also in those
molecules present on the surface of the cell membrane, induc-
ing apoptosis of cells that produce TNF-.8
Often is difﬁcult to carry out a clinical joint evaluation,
making it impossible to verify the disease activity. Thus,
the continuity of treatment proceeds on empirically, and not
based on pathophysiological characteristics. It is notewor-
thy that the disease usually accompanies the patient for life,
with periods of exacerbation and inactivity, and in many
cases, one cannot differentiate these stages only with clinical
assessment.9
Based on the speciﬁc binding ability of anti-CD3 complex
monoclonal antibodies present in joint inﬂammatory reac-
tions when the disease is active, as in JIA, it was possible to
devise a diagnostic method using gamma-emitting radionu-
clide (technetium-99m–99mTc) coupled to these molecules.
The aim of this study was to demonstrate the potential of
99mTc-OKT3 scintigraphy to assess disease activity and the
therapeutic response in a female patient with juvenile idio-
pathic arthritis.
Case  report
Female Caucasian patient, 16 years old, 46 kg, 1.63 m,  diag-
nosed eight years ago with severe systemic onset polyarticular
course JIA refractory to multiple DMARDS, and in continuous
treatment with prednisone and azathioprine. The difﬁcult-to-
control disease was active and with an intense inﬂammatory
reaction: polyarthritis of small and large joints, presence
of synovial cysts, fever and deterioration of general con-
dition. Laboratory tests: RBC 4.69 × 106 mm−3, hematocrit
37.9%, leukocytes 8.1 × 103 mm−3, platelets 569 × 103 mm−3,
negative serology for hepatitis B and C, CRP 12.1 mg/dL
(normal < 0.5 mg/dL), erythrocyte sedimentation rate (ESR)
90 mm (normal < 10 mm).  Rheumatoid factor, ANA, and VDRL
were negative. She presented arthritis (pain and swelling)
in 21 joints; global assessment by visual analogue scale
(VAS): patient 8/physician 8; DAS 28 (ESR) 7.94 – (high dis-
ease activity). Due to the intense inﬂammatory activity, the
patient had been treated with intravenous immunoglobulin
plus deﬂazacort, prednisone, methotrexate, azathioprine, and
leﬂunomide. With this severe condition, treatment with an
anti-TNF inhibitor at a dose of 5 mg/kg every 8 weeks was indi-Please cite this article in press as: Lopes FP, et al. Reduced activation
uation of clinical and 99mTc-OKT3 scintigraphic response in a pati
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cated. The initial evaluation with chest X-ray was normal and
the PPD test was negative (with BCG scar). Before the use of bio-
logical medication, a baseline 99mTc-OKT3scintigraphy was
performed. The parents signed an informed consent form for 1 6;x  x x(x x):xxx–xxx
both procedures and the study was approved by the Research
Ethics Committee of HUCFF/UFRJ (protocol 080/03). The initial
scintigraphy (Fig. 1A) with anterior and posterior whole-body
scans were obtained 1 h and 3 h after intravenous admin-
istration of 99mTc-OKT3, showed normal biodistribution of
the radiopharmaceutical in the liver and kidneys, with areas
of increased uptake in hands-phalanges, lower limbs, knees
and ankles (more pronounced in wrists, ankles and knees).
By comparing early (1 h) and late (3 h) images, a signiﬁcant
increase in radiopharmaceutical uptake was noted. This pro-
cedure detects inﬂammatory polyarticular involvement, but it
is worth mentioning that its speciﬁcity for CD3T cells demon-
strates the intense activity and the presence of these cells in
joint tissues.
After a 10-month treatment with anti-TNF blocker at
a dose of 5 mg/kg every 8 weeks, and with the patient
in use of stable doses of azathioprine, prednisone and
a non-steroidal anti-inﬂammatory agent, improvement of
the clinical parameters was observed. The fever disap-
peared. Laboratory tests: RBC 4.74 × 106 mm−3, hematocrit
36.2%, leukocytes 10.1 × 103 mm−3, platelets 458 × 103 mm−3,
CRP 12.3 mg/dL, erythrocyte sedimentation rate (ESR) 64 mm.
Arthritis (pain and swelling) was observed in two  joints; global
assessment scale – patient 2/physician 2; DAS 28 (ESR) 3.99
– moderate disease activity. In the post-treatment scintig-
raphy (ten months after the use of anti-TNF-alpha [Fig. 1,
lower segment]), areas of uptake in feet, ankles, knees, wrists
and hands were observed. In the comparative analysis versus
the pretreatment study, there is intense inﬂammatory activ-
ity (but to a lesser degree) in feet, ankles, knees, wrists and
hands, showing a decrease in the inﬂammatory process, but
with persistent active disease despite clinical and laboratory
improvement.
Discussion
Following treatment with an anti-TNF-inhibitor, our patient
improved her clinical parameters and also with respect to:
DAS 28, a 49.8% decrease; VAS by patient and physician, 75%.
As to acute phase reactants, CRP denoted no change, with
ESR decreasing 29%. It can be noted that, in the face of a
very aggressive disease, the clinical and laboratory parameters
improved with the patient’s treatment. Baseline 99mTc-OKT3
scintigraphy (Fig. 1, upper segment) showed sensitivity to the
presence of a rheumatoid inﬂammatory process, with intense
uptake at the level of inﬂamed joints, in agreement with the
patient’s initial clinical status, joint examination and tests for
acute phase reactants. The scintigraphy study also demon-
strated an ability to qualify the presence of CD3-dependent
inﬂammatory reaction, caused by the intense presentation
and activation of immune cells, thus characterizing the pres-
ence of CD3 in the joint. The scintigraphy study carried out
after 10 months of treatment with TNF blocker (Fig. 1, lower
segment) revealed signiﬁcant decrease in CD3 uptake in joints,
paralleling the clinical and joint improvement, as well as and CD3 lymphocyte recruitment after TNF-inhibitor use: eval-
ent with juvenile idiopathic arthritis. Rev Bras Reumatol. 2016.
ESR. This fact supports the reduction of inﬂammatory activ-
ity, particularly that dependent on CD3. Another important
factor is that, notwithstanding the important objective clin-
ical response observed, 99mTc-OKT3 scintigraphy made it
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Fig. 1 – 99mTc-OKT3 scintigraphy images before (A) and after (B) the use of anti-TNF-inhibitor, demonstrating ankles, knees
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ossible to detect activity of the still present disease, leading
o a continuation of treatment with anti-TNF-inhibitor, until
emission was achieved.
The study with anti-CD3 monoclonal antibody (OKT3) tar-
eted against human CD3-cell molecules and labelled with
echnetium-99m in JIA patients showed marked radiotracer
ptake in inﬂamed joints, secondarily to lymphocyte activa-
ion and proliferation, especially with respect to CD3, related
o the severity of synovial inﬂammation.10 The purpose of this
bservation is to evaluate, using 99mTc-OKT3 scintigraphy,
he aggression to joint and synovial structures, the clinical
ction of anti-TNF-inhibitor, its effects on the inﬂammatory
oint process, and the recruitment and activation of CD3 lym-
hocytes in the joints of a patient with rheumatoid disease.
Although other studies have described the occurrence of
ide effects after administration of 99mTc-OKT3, these draw-
acks were not observed after the use of 99mTc-OKT3 in
his study. It is noteworthy that the OKT3 labelling methods
escribed by other authors11 were different, implying even
ifferences in the accumulation and clearing of radiotracers.
These results demonstrate improvement of signs and
ymptoms with anti-TNF alpha monoclonal antibody therapy,
ith marked decrease in inﬂammatory activity in synovial
issues of the rheumatoid arthritis patient. The 99mTc-OKT3
cintigraphy study was able to demonstrate sensitivity, indi-
ating increased presence of CD3 in joint structures, and its
ecline after speciﬁc treatment, with a decrease in inﬂamma-
ory activity in synovial tissues, and also demonstrates diseasePlease cite this article in press as: Lopes FP, et al. Reduced activation
uation of clinical and 99mTc-OKT3 scintigraphic response in a pati
http://dx.doi.org/10.1016/j.rbre.2015.08.011
ctivity, despite a marked clinical and laboratory improve-
ent. The results showed that this method was able to capture
he recruitment restriction, activation of CD3 molecule anddecrease of activity of inﬂammatory cells such as CD4 and CD8
cells,12 secondary to the use of anti-TNF-inhibitor. Thus, we
presume that this method could become an important adju-
vant in the diagnosis and monitoring of treatment of patients
with rheumatoid arthritis, especially in those difﬁcult-to-
evaluate cases; and also, perhaps, in optimizing the therapy
for patients who, at the time of the examination, demonstrate
inactivity of the disease (absence of abnormal uptake of the
radiopharmaceutical).
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